Changes in:
Accounts receivable 111 (1,029)
Inventories 269 988
Prepaid expenses and other current assets 472 483
Deposits other than on property and
equipment, and other assets (250) 250
Accounts payable 931 706
Accrued expenses (657) (1,975)
Deferred product revenue - (189)
Net cash used in operating activities (15,043) (28,662)
Cash flows from investing activities:
Repurchase of Keflex assets from Deerfield (12,190) -
Purchases of marketable securities (11,240) (5,868)
Sale and maturities of marketable securities 2,380 5,530
Purchases of property and equipment (39) (246)
Deposits on property and equipment - (1,150)
Proceeds from sale of fixed assets 472 -
Net cash used in investing activities (20,617) (1,734)
Cash flows from financing activities:
Proceeds from private placement of common
stock, net of issue costs 115,943 22,412
Payments on lines of credit - (2,000)
Proceeds from exercise of common stock
options 758 115
Proceeds from exercise of common stock
warrants 164 -
Payment to settle warrant liability (8,814) -
Net cash provided by financing
activities
'/>"/>
| SOURCE MiddleBrook Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved |